Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Septic Shock Overview 9
Therapeutics Development 10
Pipeline Products for Septic Shock - Overview 10
Pipeline Products for Septic Shock - Comparative Analysis 11
Septic Shock - Therapeutics under Development by Companies 12
Septic Shock - Therapeutics under Investigation by Universities/Institutes 14
Septic Shock - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Septic Shock - Products under Development by Companies 19
Septic Shock - Products under Investigation by Universities/Institutes 20
Septic Shock - Companies Involved in Therapeutics Development 21
Adrenomed AG 21
Ferring International Center S.A. 22
Huons Co., Ltd. 23
InflaRx GmbH 24
Inotrem S.A. 25
Lixte Biotechnology Holdings, Inc. 26
Noxxon Pharma AG 27
Octapharma AG 28
Orion Oyj 29
Peptinov SAS 30
Pharmazz, Inc. 31
Spider Biotech 32
Takeda Pharmaceutical Company Limited 33
Therashock, LLC 34
ViiV Healthcare Limited 35
XImmune AB 36
Septic Shock - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
3K3A-APC - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
adrecizumab - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AM-12 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Aspidasept - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
BC-1215 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
BMS-936559 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
BTZO-2 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Drug for Sepsis and Septic Shock - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
HBN-1 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
HBN-3 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
HBN-4 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
HU-003 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
IFX-1 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
L-257 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
LB-100 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
levosimendan - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
M-6229 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Motrem - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
NOXD-21 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
PMZ-2010 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
pooled plasma (human) - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
R-190 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
SB-056 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
selepressin - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
SP-14 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
SP-9 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Septic Shock - Dormant Projects 83
Septic Shock - Discontinued Products 85
Septic Shock - Product Development Milestones 86
Featured News & Press Releases 86
Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock 86
Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery 86
Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody 87
Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan 88
Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients 89
Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables
Number of Products under Development for Septic Shock, H2 2016 10
Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Septic Shock - Pipeline by Adrenomed AG, H2 2016 21
Septic Shock - Pipeline by Ferring International Center S.A., H2 2016 22
Septic Shock - Pipeline by Huons Co., Ltd., H2 2016 23
Septic Shock - Pipeline by InflaRx GmbH, H2 2016 24
Septic Shock - Pipeline by Inotrem S.A., H2 2016 25
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 26
Septic Shock - Pipeline by Noxxon Pharma AG, H2 2016 27
Septic Shock - Pipeline by Octapharma AG, H2 2016 28
Septic Shock - Pipeline by Orion Oyj, H2 2016 29
Septic Shock - Pipeline by Peptinov SAS, H2 2016 30
Septic Shock - Pipeline by Pharmazz, Inc., H2 2016 31
Septic Shock - Pipeline by Spider Biotech, H2 2016 32
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 33
Septic Shock - Pipeline by Therashock, LLC, H2 2016 34
Septic Shock - Pipeline by ViiV Healthcare Limited, H2 2016 35
Septic Shock - Pipeline by XImmune AB, H2 2016 36
Assessment by Monotherapy Products, H2 2016 37
Number of Products by Stage and Target, H2 2016 39
Number of Products by Stage and Mechanism of Action, H2 2016 41
Number of Products by Stage and Route of Administration, H2 2016 43
Number of Products by Stage and Molecule Type, H2 2016 45
Septic Shock - Dormant Projects, H2 2016 83
Septic Shock - Dormant Projects (Contd..1), H2 2016 84
Septic Shock - Discontinued Products, H2 2016 85

List of Figures
Number of Products under Development for Septic Shock, H2 2016 10
Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 37
Number of Products by Top 10 Targets, H2 2016 38
Number of Products by Stage and Top 10 Targets, H2 2016 38
Number of Products by Top 10 Mechanism of Actions, H2 2016 40
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 40
Number of Products by Routes of Administration, H2 2016 42
Number of Products by Stage and Routes of Administration, H2 2016 42
Number of Products by Molecule Types, H2 2016 44
Number of Products by Stage and Molecule Types, H2 2016 44